Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
3,508,502
-
Share change
-
+923,070
-
Total reported value
-
$70,462,026
-
Put/Call ratio
-
80%
-
Price per share
-
$20.10
-
Number of holders
-
58
-
Value change
-
+$18,617,431
-
Number of buys
-
42
-
Number of sells
-
9
Institutional Holders of ZYNERBA PHARMACEUTICALS INC - COM (ZYNE) as of Q1 2017
As of 31 Mar 2017,
ZYNERBA PHARMACEUTICALS INC - COM (ZYNE) was held by
58 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,508,502 shares.
The largest 10 holders included
Cormorant Asset Management, LLC, Marshall Wace North America L.P., VANGUARD GROUP INC, CITADEL ADVISORS LLC, PERCEPTIVE ADVISORS LLC, BlackRock Inc., SPHERA FUNDS MANAGEMENT LTD., Granite Point Capital Management, L.P., MARSHALL WACE ASIA Ltd, and GOLDMAN SACHS GROUP INC.
This page lists
58
institutional shareholders reporting positions in this security
for the Q1 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.